Clinical Trial Goal
To find out:
- The highest dose of iberdomide that's safe to give with elotuzumab
- If the combination of elotuzumab and iberdomide after CAR T-cell therapy is safe and works well to treat multiple myeloma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have multiple myeloma that has relapsed or is refractory
- Have received ide-cell CAR T-cell therapy within the last 3 months
- Have been treated with all of the following (your doctor can tell you this):
- anti CD38 monoclonal antibody
- Immunomodulating agent
- Proteasome inhibitor
- Do not have any of the following:
- Amyloidosis
- Plasma cell leukemia
- POEMS syndrome
- Have not been treated with iberdomide
- Have not had blood or marrow transplant (BMT) in the last 3 months
- Do not have graft-versus-host-disease (GVHD)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Elotuzumab is a monoclonal antibody that targets SLAMF7 in some cancer cells.
Iberdomide is a cereblon E3 ligase modulator.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
Iberdomide is a cereblon E3 ligase modulator.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- Elotuzumab – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
- Iberdomide – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 4 years.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them in this way after CAR T-cell therapy, to treat multiple myeloma that has relapsed or is refractory, is new and unproven.
Locations
Brigham and Women's HospitalNOT_YET_RECRUITING
Boston, Massachusetts
Omar Nadeem, MD, 617-632-4703, Omar_Nadeem@dfci.harvard.edu
Beth Israel Deaconess Medical CenterRECRUITING
Boston, Massachusetts
David Avigan, MD, 617-667-9920, davigan@bidmc.harvard.edu
Dana Farber Cancer InstituteRECRUITING
Boston, Massachusetts
Omar Nadeem, MD, 617-632-4703, Omar_Nadeem@dfci.harvard.edu
Sponsors
collaborator: Celgene, collaborator: Bristol-Myers Squibb, lead: Omar Nadeem, MD
